


## PHARMACEUTICAL 2022



## PLIANT THERAPEUTICS INC. Rank 141 of 466





## PHARMACEUTICAL 2022



## PLIANT THERAPEUTICS INC. Rank 141 of 466

The relative strengths and weaknesses of PLIANT THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLIANT THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 59% points. The greatest weakness of PLIANT THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 201%, being 123% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	209,441
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,831
Liabilities, Non-Current	5,325
Other Assets	7,168
Other Compr. Net Income	-169
Other Expenses	0
Other Liabilities	0
Other Net Income	272
Other Revenues	7,572
Property and Equipment	4,606
Research and Development	77,549
Selling, General and Administrative Expense	27,558

Output Variable	Value in 1000 USD
Assets	221,215
Liabilities	22,156
Expenses	105,107
Revenues	7,572
Stockholders Equity	199,059
Net Income	-97,263
Comprehensive Net Income	-97,348
Economic Capital Ratio	201%